Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carcinoma

The first-line treatment for advanced hepatocellular carcinoma (HCC) is atezolizumab plus bevacizumab, but its availability is not universal and elderly patients are underrepresented in clinical trials. There is little evidence of efficacy and tolerability in elderly patients under systemic treatmen...

Descripción completa

Detalles Bibliográficos
Autores: Soria, Anna|||0000-0001-5671-8343, Calvo, Mariona|||0000-0001-6242-0500, Casas, Meritxell|||0000-0001-7227-7277, Vidales, Zara, Muñoz-Martínez, S|||0000-0003-0663-0575, Sapena, Victor|||0000-0003-4379-6486, Puigvehí, Marc|||0000-0002-3694-3241, Canillas, Lidia, Guardeño, Raquel, Gallego, Adolfo, Mínguez Rosique, Beatriz|||0000-0002-7276-9666, Horta Sangenís, Diana|||0000-0002-3675-1135, Clos, Ariadna|||0000-0002-6414-2097, Montoliu, Silvia|||0000-0002-3041-578X, Roget, Mercè, Reig, María|||0000-0002-5711-9534, Vergara, Mercedes|||0000-0002-6971-8657
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:282705
Acceso en línea:https://ddd.uab.cat/record/282705
https://dx.doi.org/urn:doi:10.3389/fonc.2022.829483
Access Level:acceso abierto
Palabra clave:Elderly patients
Hepatocellular carcinoma
Outcome
Overall survival
Safety
Sorafenib
Descripción
Sumario:The first-line treatment for advanced hepatocellular carcinoma (HCC) is atezolizumab plus bevacizumab, but its availability is not universal and elderly patients are underrepresented in clinical trials. There is little evidence of efficacy and tolerability in elderly patients under systemic treatment. The aims of this study were to characterize the profile of elderly patients treated with sorafenib, assess their survival and safety profile in order to extrapolate their eligibility for systemic treatment. Retrospective multicentre study of HCC patients aged ≥75 years old treated with sorafenib from January 2008 to December 2019. Demographic data, baseline characteristics, and variables related to HCC and sorafenib were recorded. Overall survival (OS) and safety were analyzed. The study included 206 patients from 11 hospitals, median age 77.9 years; 71.4% men and 62.6% stage Barcelona Clinic Liver Cancer- C (BCLC-C). The main causes of cirrhosis were hepatitis C (60.7%) and alcohol (14.7%). Most patients (84.5%) started with sorafenib 800mg and 15.5% at lower dosage. Arterial hypertension (AHT) (74.2 vs 62.2%; standardized mean differences (STD): 26) and baseline ECOG-PS

Similares en LA Referencia